This announcement is a separate document:
荣昌生物制药（烟台）股份有限公司2024年半年度报告摘要
Summary of Remegen (Yantai) Co., Ltd.'s 2024 Interim Report
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.